{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:33:44Z","timestamp":1792787624730,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"French Ministry of Health"},{"name":"French Ministry of Health"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Composite outcomes are commonly used in critical care trials to estimate the treatment effect of an intervention. A significant limitation of classical analytic approaches is that they assign equal statistical importance to each component in a composite, even if these do not have the same clinical importance (i.e., in a composite of death and organ failure, death is clearly more important). The win ratio (WR) method has been proposed as an alternative for trial outcomes evaluation, as it effectively assesses events based on their clinical relevance (i.e., hierarchical order) by comparing each patient in the intervention group with their counterparts in the control group. This statistical approach is increasingly used in cardiovascular outcome trials. However, WR may be useful to unveil treatment effects also in the critical care setting, because these trials are typically moderately sized, thus limiting the statistical power to detect small differences between groups, and often rely on composite outcomes that include several components of different clinical importance. Notably, the advantages of this approach may be offset by several drawbacks (such as ignoring ties and difficulties in selecting and ranking endpoints) and challenges in appropriate clinical interpretation (i.e., establishing clinical meaningfulness of the observed effect size). In this perspective article, we present some key elements to implementing WR statistics in critical care trials, providing an overview of strengths, drawbacks, and potential applications of this method. To illustrate, we conduct a reevaluation of the HYPO-ECMO (Hypothermia during Venoarterial Extracorporeal Membrane Oxygenation) trial using the WR framework as a case example.<\/jats:p>","DOI":"10.1164\/rccm.202309-1644cp","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T12:24:15Z","timestamp":1706531055000},"page":"798-804","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":16,"title":["Use of the Win Ratio Analysis in Critical Care Trials"],"prefix":"10.1093","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2958-943X","authenticated-orcid":false,"given":"Luca","family":"Monzo","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1116, Nancy, France"},{"name":"Centre Hospitalier R\u00e9gional Universitaire de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, France"},{"name":"INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN (French Clinical Research Infrastructure Network), Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[{"name":"Centre Hospitalier R\u00e9gional Universitaire de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, France"},{"name":"Universit\u00e9 de Lorraine, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1116, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Duarte","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1116, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Baudry","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1116, Nancy, France"},{"name":"Centre Hospitalier R\u00e9gional Universitaire de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, France"},{"name":"INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN (French Clinical Research Infrastructure Network), Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Combes","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Intensive-R\u00e9animation H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Ouattara","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Bordeaux, Department of Anaesthesia and Critical Care, Magellan Medico-Surgical Centre, Bordeaux, France"},{"name":"University Bordeaux, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Unit\u00e9s Mixtes de Recherche 1034, Biology of Cardiovascular Diseases, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Delmas","sequence":"additional","affiliation":[{"name":"Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-2074","authenticated-orcid":false,"given":"Antoine","family":"Kimmoun","sequence":"additional","affiliation":[{"name":"Centre Hospitalier R\u00e9gional Universitaire de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, France"},{"name":"Universit\u00e9 de Lorraine, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1116, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1116, Nancy, France"},{"name":"Centre Hospitalier R\u00e9gional Universitaire de Nancy, Institut Lorrain du Coeur et des Vaisseaux, Nancy, France"},{"name":"INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN (French Clinical Research Infrastructure Network), Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"2026012204272780400_bib1","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1164\/rccm.201401-0056CP","article-title":"Outcomes and statistical power in adult critical care randomized trials","volume":"189","author":"Harhay","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204272780400_bib2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials","volume":"334","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"BMJ"},{"key":"2026012204272780400_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012204272780400_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012204272780400_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026012204272780400_bib6","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"2026012204272780400_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacbts.2023.05.004","article-title":"Fallacies of using the win ratio in cardiovascular trials: challenges and solutions","volume":"8","author":"Ajufo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2026012204272780400_bib8","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: practical guidance based on previous experience","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012204272780400_bib9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/sim.9297","article-title":"Sample size formula for a win ratio endpoint","volume":"41","author":"Yu","year":"2022","journal-title":"Stat Med"},{"key":"2026012204272780400_bib10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pst.1763","article-title":"A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components","volume":"15","author":"Dong","year":"2016","journal-title":"Pharm Stat"},{"key":"2026012204272780400_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/10543406.2020.1757690","article-title":"The use of the win odds in the design of non-inferiority clinical trials","volume":"30","author":"Peng","year":"2020","journal-title":"J Biopharm Stat"},{"key":"2026012204272780400_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026012204272780400_bib13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","article-title":"Unlocking the DOOR: how to design, apply, analyse, and interpret desirability of outcome ranking (DOOR) endpoints in infectious diseases clinical trials","volume":"29","author":"Ong","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026012204272780400_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s13054-020-03113-z","article-title":"Identification, collection, and reporting of harms among non-industry-sponsored randomized clinical trials of pharmacologic interventions in the critically ill population: a systematic review","volume":"24","author":"Moskowitz","year":"2020","journal-title":"Crit Care"},{"key":"2026012204272780400_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0962280210394479","article-title":"Practical methods for competing risks data: a review","volume":"21","author":"Bakoyannis","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"2026012204272780400_bib16","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012204272780400_bib17","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa2100591","article-title":"Hypothermia versus normothermia after out-of-hospital cardiac arrest","volume":"384","author":"Dankiewicz","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012204272780400_bib18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s00134-021-06505-z","article-title":"Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets","volume":"47","author":"Fernando","year":"2021","journal-title":"Intensive Care Med"},{"key":"2026012204272780400_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.117.032722","article-title":"Mild hypothermia in cardiogenic shock complicating myocardial infarction","volume":"139","author":"Fuernau","year":"2019","journal-title":"Circulation"},{"key":"2026012204272780400_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00392-020-01652-7","article-title":"Hypothermia in patients with acute myocardial infarction: a meta-analysis of randomized trials","volume":"110","author":"Alushi","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026012204272780400_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jama.2021.24776","article-title":"Effect of moderate hypothermia vs normothermia on 30-day mortality in patients with cardiogenic shock receiving venoarterial extracorporeal membrane oxygenation: a randomized clinical trial","volume":"327","author":"Levy","year":"2022","journal-title":"JAMA"},{"key":"2026012204272780400_bib22","doi-asserted-by":"crossref","first-page":"e031697","DOI":"10.1136\/bmjopen-2019-031697","article-title":"Protocol for a multicentre randomised controlled trial evaluating the effects of moderate hypothermia versus normothermia on mortality in patients with refractory cardiogenic shock rescued by venoarterial extracorporeal membrane oxygenation (VA-ECMO) (HYPO-ECMO study)","volume":"9","author":"Jacquot","year":"2019","journal-title":"BMJ Open"},{"key":"2026012204272780400_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jchf.2020.02.010","article-title":"Use of the win ratio in cardiovascular trials","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/7\/798\/66426383\/ajrccm_209_7_798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/7\/798\/66426383\/ajrccm_209_7_798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:27:37Z","timestamp":1769074057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/209\/7\/798\/8426988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202309-1644cp","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}